Erste Group Bank Has Positive Outlook of BMY FY2026 Earnings

Bristol Myers Squibb Company (NYSE:BMY) – Equities research analysts at Erste Group Bank boosted their FY2026 earnings per share estimates for shares of Bristol Myers Squibb in a report released on Tuesday, March 24th. Erste Group Bank analyst H. Engel now anticipates that the biopharmaceutical company will post earnings per share of $6.29 for the year, up from their prior estimate of $6.28. The consensus estimate for Bristol Myers Squibb’s current full-year earnings is $6.74 per share. Erste Group Bank also issued estimates for Bristol Myers Squibb’s FY2027 earnings at $6.12 EPS.

A number of other equities research analysts have also recently commented on the stock. Piper Sandler restated an “overweight” rating and set a $75.00 target price (up from $66.00) on shares of Bristol Myers Squibb in a research note on Monday, February 23rd. Royal Bank Of Canada began coverage on shares of Bristol Myers Squibb in a research report on Tuesday, February 24th. They issued a “sector perform” rating and a $60.00 price target for the company. Citigroup increased their price objective on shares of Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a “neutral” rating in a research note on Friday, February 6th. Barclays initiated coverage on shares of Bristol Myers Squibb in a research note on Thursday, February 19th. They set an “overweight” rating and a $75.00 target price on the stock. Finally, Scotiabank reaffirmed a “sector perform” rating and issued a $60.00 target price (up from $53.00) on shares of Bristol Myers Squibb in a report on Friday, January 9th. Nine research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $61.41.

Bristol Myers Squibb Stock Up 0.8%

BMY stock opened at $59.40 on Thursday. The business’s 50-day moving average price is $58.75 and its 200-day moving average price is $52.11. The stock has a market cap of $120.97 billion, a P/E ratio of 17.22, a PEG ratio of 0.17 and a beta of 0.26. The company has a quick ratio of 1.14, a current ratio of 1.26 and a debt-to-equity ratio of 2.32. Bristol Myers Squibb has a twelve month low of $42.52 and a twelve month high of $62.89.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.65 by ($0.39). Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The company had revenue of $12.50 billion for the quarter, compared to the consensus estimate of $12.24 billion. During the same period in the prior year, the firm posted $1.67 EPS. The business’s revenue for the quarter was up 1.3% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS.

Hedge Funds Weigh In On Bristol Myers Squibb

Several institutional investors have recently bought and sold shares of the stock. Norges Bank purchased a new position in shares of Bristol Myers Squibb during the fourth quarter valued at about $1,947,272,000. AQR Capital Management LLC lifted its position in shares of Bristol Myers Squibb by 172.6% in the fourth quarter. AQR Capital Management LLC now owns 25,796,905 shares of the biopharmaceutical company’s stock worth $1,391,485,000 after buying an additional 16,332,924 shares in the last quarter. Arrowstreet Capital Limited Partnership boosted its stake in Bristol Myers Squibb by 428.5% during the second quarter. Arrowstreet Capital Limited Partnership now owns 11,311,281 shares of the biopharmaceutical company’s stock valued at $523,599,000 after buying an additional 9,171,098 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in Bristol Myers Squibb by 47.0% during the 4th quarter. Bank of New York Mellon Corp now owns 24,495,875 shares of the biopharmaceutical company’s stock valued at $1,321,308,000 after buying an additional 7,837,485 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in Bristol Myers Squibb by 13.1% in the 4th quarter. Geode Capital Management LLC now owns 52,638,346 shares of the biopharmaceutical company’s stock worth $2,837,026,000 after acquiring an additional 6,084,046 shares during the last quarter. 76.41% of the stock is owned by hedge funds and other institutional investors.

Bristol Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, May 1st. Stockholders of record on Thursday, April 2nd will be issued a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 4.2%. The ex-dividend date of this dividend is Thursday, April 2nd. Bristol Myers Squibb’s payout ratio is 73.04%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.